BJCP British Journal of Clinical Pharmacology

DOI:10.1111/j.1365-2125.2008.03210.x

AUTHOR INDEX

A, J.Y. *see* QIU, F.R.
AAGAARD, L., SOENDERGAARD, B., STENVER, D.I. & HANSEN, E.H. Knowledge creation about ADRs – turning the perspective from the rear mirror to the projector?: 364
ABILDSTROM, S.Z. *see* HANSEN, M.L.
ALBERS, S., MEIBOHM, B., MIR, T.S. & LÄER, S. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure: 511
ALMER, S. *see* HAGLUND, S.
ALVÁN, G. *see* TERNANT, D.
ANDERSON, W.J. *see* CURRIE, G.P.
ANDREWS, E., DAMLE, B.D., FANG, A., FOSTER, G., CROWNOVER, P., LABADIE, R. & GLUE, P. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects: 531
ANGELICI, L. *see* BERTELE', V.
ANITHA, S. *see* BAKSHI, S.
ANOSIKE, C. *see* MOLOKWU, C.N.
ARONSON, J.K., COHEN, A. & LEWIS, L.D. Clinical pharmacology – providing tools and expertise for translational medicine: 154
ARULMANI, R., RAJENDRAN, S.D. & SURESH, B. Adverse drug reaction monitoring in a secondary care hospital in South India: 210
ATTHOBARI, J. *see* BOERSMA, C.
ATTWOOD, B. *see* CAMIDGE, D.R.
AULELEY, S. *see* HIRT, D.
AUTRET-LECA, E. *see* BLASCO, H.
AUTRET-LECA, E. *see* JONVILLE-BÉRA, A.P.
AVERY, A.J. *see* KRSKA, J.

BÉLANGER, F. *see* ZAKRZEWSKI-JAKUBIAK, M.
BÉNÉTON, M. *see* TERNANT, D.
BÖGER, R.H. *see* BIEREND, A.
BÖGER, R.H. *see* SCHWEDHELM, E.
BÜCHLER, M. *see* TERNANT, D.
BÜRKI, F., BADIE, K., BARTOLI, P., BERNARD, P., MONTASTRUC, J.L. & BAGHERI, H. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen: 793
BACK, D.J. & GIBBONS, S.E. Response to 'Communicating Information about Drug Interactions': 617
BADIE, K. *see* BÜRKI, F.
BAGHERI, H. *see* BÜRKI, F.
BAIWOG, F. *see* LAW, I.
BAKKER, M.K., KÖLLING, P., VAN DEN BERG, P.B., DE WALLE, H.E.K. & DE JONG VAN DEN BERG, L.T.W. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands: 600
BAKSHI, S., RAMACHANDRAN, G., RAMESH, K., HEMANTHKUMAR, A.K., ANITHA, S., PADMAPRIYADARSINI, C., NARENDRAN, G., MENON, P.A., RAJASEKARAN, S. & SWAMINATHAN, S. Study of *ABCB1* polymorphism (C3435T) in HIV-1-infected individuals from South India: 791
BALAKRISHNAN, S. & JHAJ, R. Prophylactic use of gastro-protective agents in patients on low-dose aspirin: 621
BALDWIN, R.M., OHLSSON, S., PEDERSEN, R.S., MWINYI, J., INGELMAN-SUNDBERG, M., ELIASSON, E & BERTILSSON, L. Increased omeprazole metabolism in carriers of the *CYP2C19*17* allele; a pharmacokinetic study in healthy volunteers: 767
BALLINGER, J.R. *see* RUPARELIA, P.
BANNEY, L. *see* RUPARELIA, P.
BARBER, N. *see* DONYAI, P.
BARLERA, S. *see* BERTELE', V.
BARNES, K.I. *see* MEHTA, U.
BARTOLI, P. *see* BÜRKI, F.
BATE, A. *see* STRANDELL, J.
BEAUCHESNE, M.-F. *see* CYR, M.-C.
BECH, J.N. *see* VASE, H.
BEGG, E.J. Prescribing in pregnancy and lactation: 627
BELLER, C.L. *see* TRAN, A.
BELON, P. *see* PARIS, A.
BENGTSSON, T. *see* PETTERSSON, J.
BENOWITZ, N. *see* HALLER, C.A.
BERNARD, P. *see* BÜRKI, F.
BERTELE', V., ANGELICI, L., BARLERA, S. & GARATTINI, S. Thrombolysis or nothing for acute myocardial infarction? It's all the same!: 955
BERTILSSON, L. *see* BALDWIN, R.M.
BERTILSSON, L. *see* WIDE, K.
BIEREND, A., RAU, T., MAAS, R., SCHWEDHELM, E. & BÖGER, R.H. *$P2Y_{12}$* polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease: 540
BIJL, M.J., VISSER, L.E., HOFMAN, A., VULTO, A.G., VAN GELDER, T., STRICKER, B.H.CH. & VAN SCHAIK, R.H.N. Influence of the *CYP2D6*4* polymorphism on dose, switching and discontinuation of antidepressants: 558
BLAIS, L. *see* CYR, M.-C.
BLASCO, H., BOISDRON-CELLE, M., BOUGNOUX, P., CALAIS, G., TOURNAMILLE, J.-F., CICCOLINI, J., AUTRET-LECA, E. & GUELLEC, C.L. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient: 966
BLIZIOTIS, I.A. *see* FALAGAS, M.E.
BLOCKMAN, M. *see* MEHTA, U.
BOERSMA, C., POSTMA, M.J., VISSER, S.T., ATTHOBARI, J., DE JONG, P.E., DE JONG-VAN DEN BERG, L.T.W. & GANSEVOORT, R.T. on behalf of the PREVEND Study Group. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in

© 2008 Blackwell Publishing Ltd

preventing cardiovascular events: 723
BOISDRON-CELLE, M. *see* BLASCO, H.
BORLAK, J. *see* PHAM, V.V.
BORRILL, Z.L., HOUGHTON, C.M., TAL-SINGER, R., VESSEY, S.R., FAIFERMAN, I., LANGLEY, S.J. & SINGH, D. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD: 244
BOUGNOUX, P. *see* BLASCO, H.
BOURNERIAS, F. *see* TRAN, A.
BRAAM, R.L., VAN UUM, S.H.M., LENDERS, J.W.M. & THIEN, T. Bromide as marker for drug adherence in hypertensive patients: 733
BRACKE, M. *see* DE VRIES, F.
BRAIN, E.G.C., REZAI, K., LOKIEC, F., GUTIERREZ, M. & URIEN, S. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an $n = 1$ randomized study: 607
BRAMNESS, J.G. *see* ENGELAND, A.
BRENNINKMEIJER, V.J. *see* HOUGARDY, D.M.C.
BROEYER, F.J.F., VAN AKEN, B.E., SUZUKI, J., KEMME, M.J.B., SCHOEMAKER, H.C., COHEN, A.F., MIZUSHIMA, Y. & BURGGRAAF, J. The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man: 22
BROSEN, K. *see* HALLING, J.
BROWN, M.J. & TOAL, C.B. Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients: 646
BROWN, S.G.A. *see* ISBISTER, G.K.
BUCH, P. *see* HANSEN, M.L.
BURGGRAAF, J. *see* BROEYER, F.J.F.
BUTLER, C.A. *see* CURRIE, G.P.

CALAIS, G. *see* BLASCO, H.
CAMIDGE, D.R., OLIVER, J.J., SKINNER, C., ATTWOOD, B., NUSSEY, F., JODRELL, D. & WEBB, D.J. The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes: 224
CAMPESTRINI, J. *see* HE, Y.-L.
CATALÁN, A. *see* FERNÁNDEZ-LIZ, E.
CHÊNE, G. *see* SALMI, L.R.
CHAGNAC, A. *see* JANMAHASATIAN, S.
CHAN, C. *see* PAN, A.X.
CHANTHARAKSRI, U. *see* LIMENTA, L.M.G.
CHAUSSARD, C. *see* PARIS, A.
CHECCHIO, T. *see* FOUNTAINE, R.
CHEOW, H.K. *see* RUPARELIA, P.
CHILVERS, E.R. *see* RUPARELIA, P.
CHO, J.-Y. *see* KIM, B.-H.
CHOW, P. *see* MAULIDI, H.
CHOWBAY, B. *see* LAL, S.
CHOWIENCZYK, P.J. *see* RAMBARAN, C.
CHRISTENSEN, S. *see* TØRRING, M.L.
CHRISTMAS, T. *see* ILETT, K.F.
CHRYSTYN, H. *see* MAZHAR, S.H.R.
CHUA, S. *see* ILETT, K.F.
CHUNG, J.-Y. *see* KIM, B.-H.
CICCOLINI, J. *see* BLASCO, H.
CLARK, S.R. *see* GUEORGUIEVA, I.
CLAUSON, P. *see* PETERSEN, A.H.
COHEN, A. *see* ARONSON, J.K.
COHEN, A.F. *see* BROEYER, F.J.F.
COLLER, J.K. *see* DAVIES, B.J.
CONTI, V. *see* CORRAO, G.
COOK, J. *see* YOUDIM, K.A.
CORRAO, G., ZAMBON, A., NICOTRA, F., CONTI, V., NAPPI, R.E. & MERLINO, L. Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study: 123
CRACOWSKI, J.L. *see* PARIS, A.
CRONENBERGER, C., MOULD, D.R., ROETHIG, H.-J. & SARKAR, M. Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers: 30
CROWNOVER, P. *see* ANDREWS, E.
CROWNOVER, P. *see* DAMLE, B.
CUBAŁA, W.J., LANDOWSKI, J. & WICHOWICZ, H.M. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects: 444
CURRIE, G.P., BUTLER, C.A., ANDERSON, W.J. & SKINNER, C. Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment: 803
CUTOLO, M. *see* MAESTRONI, G.J.
CYR, M.-C., BEAUCHESNE, M.-F., LEMIÈRE, C. & BLAIS, L. Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease: 40

DALHOFF, K.P. *see* GLINTBORG, B.
DALTVEIT, A.K. *see* ENGELAND, A.
DAMASKOS, D. & KOLIOS, G. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope': 453
DAMLE, B., LABADIE, R., CROWNOVER, P. & GLUE, P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers: 523
DAMLE, B.D. *see* ANDREWS, E.
DAREKAR, A. *see* YOUDIM, K.A.
DAVIES, B.J., HERBERT, M.K., COLLER, J.K., SOMOGYI, A.A., MILNE, R.W. & SALLUSTIO, B.C. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered *Rac*-perhexiline: 347
DAVIS, S. *see* KULKARNI, U.P.
DAVIS, T.M.E. *see* LAW, I.
DE DENUS, S. *see* ZAKRZEWSKI-JAKUBIAK, M.
DE JONG VAN DEN BERG, L.T.W. *see* BAKKER, M.K.
DE JONG, P.E. *see* BOERSMA, C.
DE JONG-VAN DEN BERG, L.T.W. *see* BOERSMA, C.
DE JONG-VAN DEN BERG, L.T.W. *see* VROOM, F.
DE LA PEÑA, A. *see* PAN, A.X.
DE LIGNY, B.H. *see* TERNANT, D.
DE VRIES, F., POUWELS, S., BRACKE, M., LAMMERS, J.-W., KLUNGEL, O., LEUFKENS, H. & VAN STAA, T. Use of β2 agonists and risk of acute myocardial infarction

in patients with hypertension: 580
DE WALLE, H.E.K. *see* BAKKER, M.K.
DELAHOUSSE, M. *see* TRAN, A.
DERIJKS, L.J.J. *see* HOUGARDY, D.M.C.
DESBOROUGH, J. *see* HOLLAND, R.
DICKINS, M. *see* YOUDIM, K.A.
DICZFALUSY, U. *see* WIDE, K.
DING, J.-J. *see* JIAO, Z.
DOLE, W.P. *see* HE, Y.-L.
DONYAI, P., O'GRADY, K., JACKLIN, A., BARBER, N. & FRANKLIN, B.D. The effects of electronic prescribing on the quality of prescribing: 230
DRUID, H. *see* WESTER, K.
DUAN, M. *see* HALLER, C.A.
DUAN, X. *see* TASHIRO, M.
DUBÉ, M.-P. *see* ZAKRZEWSKI-JAKUBIAK, M.
DUFFULL, S.B. *see* JANMAHASATIAN, S.
DURRHEIM, D.N. *see* MEHTA, U.
DUTREIX, C. *see* WANG, Y.
DUVAL, X. *see* HIRT, D.

EDWARDS, G. *see* MUCHOHI, S.N.
EDWARDS, I.R. *see* STRANDELL, J.
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients: 548
EGBERTS, A.C.G. *see* KUIJPERS, M.A.J.
EGBERTS, T.C.G. *see* HOUGARDY, D.M.C.
EISINGER, M.J. *see* HIRT, D.
EKELUND, M. *see* PETTERSSON, J.
ELIASSON, E. *see* BALDWIN, R.M.
ENDRENYI, L. *see* TOTHFALUSI, L.
ENGELAND, A., BRAMNESS, J.G., DALTVEIT, A.K., RØNNING, M., SKURTVEIT, S. & FURU, K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004–2006: 653
ERICSSON, H. *see* HAMRÉN, B.
ERNST, E. Author's response: 281
ERNST, E. The truth about homeopathy: 163
ESHIMA, N. *see* IMAI, H.
EVANS, J.W. *see* RUPARELIA, P.

FAHMI, O. *see* YOUDIM, K.A.
FAIFERMAN, I. *see* BORRILL, Z.L.
FALAGAS, M.E., PITSOUNI, E.I. & BLIZIOTIS, I.A. Trends in the methodological quality of published randomized controlled trials on antibacterial agents: 942
FANG, A. *see* ANDREWS, E.
FAREED, J. *see* KIPSHIDZE, N.N.
FAZAKAS, J. *see* KÓBORI, L.
FERNÁNDEZ-LIZ, E., MODAMIO, P., CATALÁN, A., LASTRA, C.F., RODRÍGUEZ, T. & MARIÑO, E.L. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain: 407
FOLKE, F. *see* HANSEN, M.L.
FORTWENGEL, G. Guide for Clinical Trial Staff – Implementing Good Clinical Practice, 3rd Printing: 446
FOSTER, G. *see* ANDREWS, E.
FOUNTAINE, R., MILTON, A., CHECCHIO, T., WEI, G., STOLAR, M., TEETER, J., JAEGER, R. & FRYBURG, D. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera®) pharmacokinetics: 864
FRANCK, P.F. *see* HUNFELD, N.G.
FRANKLIN, B.D. *see* DONYAI, P.
FREESE, R. *see* SCHWEDHELM, E.
FRIEDMAN, R.M. Clinical uses of interferons: 158
FROSSARD, N., STROLIN-BENEDETTI, M., PUROHIT, A. & PAULI, G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine: 172
FRYBURG, D. *see* FOUNTAINE, R.
FUCHAROEN, S. *see* LIMENTA, L.M.G.
FUJIMURA, A., YASUHARA, H. & NAKANO, S. Current status of clinical pharmacology services provided by Board Certified Clinical Pharmacologists in Japan: 442
FUNAKI, Y. *see* OKAMURA, N.
FUNAKI, Y. *see* TASHIRO, M.
FURU, K. *see* ENGELAND, A.

GALETTIS, P. *see* JIANG, X.
GANSEVOORT, R.T. *see* BOERSMA, C.
GARATTINI, S. *see* BERTELE', V.
GAUTAM, C.S. & SAHA, L. Fixed dose drug combinations (FDCs): rational or irrational: a view point: 795
GERLEI, Z. *see* KÓBORI, L.
GEUS, W.P. *see* HUNFELD, N.G.
GIBBONS, S.E. *see* BACK, D.J.
GISLASON, G.H. *see* HANSEN, M.L.
GLINTBORG, B., POULSEN, H.E. & DALHOFF, K.P. The use of nationwide on-line prescription records improves the drug history in hospitalized patients: 265
GLUE, P. *see* ANDREWS, E.
GLUE, P. *see* DAMLE, B.
GODAMBE, S. *see* MAULIDI, H.
GOGTAY, N.J. *see* KULKARNI, U.P.
GOH, B.-C. *see* LAL, S.
GOLANI, A. *see* SINGH, N.
GOMORRAI, S. *see* LAW, I.
GONG, Z.-C. *see* SUN, H.
GONNET, N. *see* PARIS, A.
GOODYER, L. *see* HOLLAND, R.
GORDI, T. *see* OBUA, C.
GORSKI, J.C. *see* QUINNEY, S.K.
GOUNDEN, R. *see* MEHTA, U.
GOY, R. *see* ILETT, K.F.
GRABOWSKI, B. *see* KHOSRAVAN, R.
GREEN, B. *see* JANMAHASATIAN, S.
GRIBNAU, F.W.J. *see* VAN LUIJN, J.C.F.
GRIFFITHS, M. *see* YOUDIM, K.A.
GRUSLANDI, M. A natural approach to treatment of inflammatory bowel disease: 468
GUDE, N.M. *see* SUDHAKARAN, S.
GUELLEC, C.L. *see* BLASCO, H.
GUEORGUIEVA, I., CLARK, S.R., MCMAHON, C.J., SCARTH, S., ROTHWELL, N.J., TYRELL, P.J., HOPKINS, S.J. & ROWLAND, M. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage: 317
GUO, F. *see* YOUDIM, K.A.
GUO, Z.-W. *see* SUN, H.
GUPTA, P., ROY, V., SETHI, G.R. & MISHRA, T.K. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses: 423
GUSTAFSSON, L.L. *see* OBUA, C.
GUTIERREZ, M. *see* BRAIN, E.G.C.

HÄGG, S. *see* WESTER, K.
HACKETT, L.P. *see* LAW, I.
HAEHNER, B.D. *see* QUINNEY, S.K.
HAGEMEISTER, T. *see* OTBERG, N.
HAGLUND, S., TAIPALENSUU, J., PETERSON, C. & ALMER, S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease – relation to TPMT activity and metabolite concentrations: 69
HALL, S. *see* HOLLAND, R.
HALL, S.D. *see* QUINNEY, S.K.
HALLER, C.A., DUAN, M., JACOB, P. III & BENOWITZ, N. Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions: 833
HALLING, J., WEIHE, P. & BROSEN, K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population: 134
HAMRÉN, B., ERICSSON, H., SAMUELSSON, O. & KARLSSON, M.O. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion: 855
HAN, P. *see* MCGETTIGAN, P.
HANSEN, E.H. *see* AAGAARD, L.
HANSEN, M.L., GISLASON, G.H., KØBER, L., SCHRAMM, T.K., FOLKE, F., BUCH, P., ABILDSTROM, S.Z., MADSEN, M., RASMUSSEN, S. & TORP-PEDERSEN, C. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction: 217
HARRISON, T.W. *see* WHALE, C.I.
HARTMAN, N.G. *see* RUPARELIA, P.
HE, Y.-L., SABO, R., CAMPESTRINI, J., WANG, Y., RIVIERE, G.-J., NIELSEN, J.C., ROSENBERG, M., LIGUEROS-SAYLAN, M., HOWARD, D. & DOLE, W.P. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers: 338
HEERINGA, J. *see* LUIJENDIJK, H.J.
HELLGREN, U. *see* OBUA, C.
HEMANTHKUMAR, A.K. *see* BAKSHI, S.
HENNIG, S., NORRIS, R. & KIRKPATRICK, C.M.J. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis – a population pharmacokinetic study: 502
HENRY, D. *see* MCGETTIGAN, P.
HERBERT, M.K. *see* DAVIES, B.J.
HINDORF, U. *see* PETTERSSON, J.
HIRT, D., MENTRÉ, F., TRAN, A., REY, E., AULELEY, S., SALMON, D., DUVAL, X., TRÉLUYER, J.-M. & The COPHAR2-ANRS Study Group.
HIRT, D., OVERMEIRE, B.V., TRELUYER, J.-M., LANGHENDRIES, J.-P., MARGUGLIO, A., EISINGER, M.J., SCHEPENS, P. & URIEN, S. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study: 629
HOFMAN, A. *see* BIJL, M.J.
HOFMAN, A. *see* LUIJENDIJK, H.J.
HOLLAND, R., DESBOROUGH, J., GOODYER, L., HALL, S., WRIGHT, D. & LOKE, Y.K. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis: 303
HOLM, L. *see* OHLSSON, S.
HOPKINS, S.J. *see* GUEORGUIEVA, I.
HORI, E. *see* UMENO, K.
HOUGARDY, D.M.C., EGBERTS, T.C.G., VAN DER GRAAF, F., BRENNINKMEIJER, V.J. & DERIJKS, L.J.J. Serotonin transporter polymorphism and bleeding time during SSRI therapy: 761
HOUGHTON, C.M. *see* BORRILL, Z.L.
HOWARD, D. *see* HE, Y.-L.
HUGHES, D.A. Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens: 871
HULL, D. *see* RAMSAY, J.
HUNFELD, N.G., MATHOT, R.A., TOUW, D.J., VAN SCHAIK, R.H., MULDER, P.G., FRANCK, P.F., KUIPERS, E.J. & GEUS, W.P. Effect of *CYP2C19* *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians: 752
HURST, S. *see* YOUDIM, K.A.
HUSSEIN, O., MINASIAN, L., ITZKOVICH, Y., SHESTATSKI, K., SOLOMON, L. & ZIDAN, J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin: 637
HYLAND, R. *see* YOUDIM, K.A.

ILETT, K.F. *see* LAW, I.
ILETT, K.F., PAECH, M.J., PAGE-SHARP, M., SY, S.K., KRISTENSEN, J.H., GOY, R., CHUA, S., CHRISTMAS, T. & SCOTT, K.L. Use of a sparse sampling study design to assess transfer of tramadol and its *O*-desmethyl metabolite into transitional breast milk: 661
IMAI, H., KOTEGAWA, T., TSUTSUMI, K., MORIMOTO, T., ESHIMA, N., NAKANO, S. & OHASHI, K. The recovery time-course of CYP3A after induction by St John's wort administration: 701
INGELMAN-SUNDBERG, M. *see* BALDWIN, R.M.
ISBISTER, G.K., O'LEARY, M., MILLER, M., BROWN, S.G.A., RAMASAMY, S., JAMES, R. & SCHNEIDER, J.S. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom: 139
ISHIKAWA, H. *see* OKAMURA, N.
ISHIKAWA, Y. *see* OKAMURA, N.
ISHIKAWA, Y. *see* TASHIRO, M.
ISMAIL, N.E. *see* MAZHAR, S.H.R.
ITOH, M. *see* TASHIRO, M.
ITZKOVICH, Y. *see* HUSSEIN, O.
IWATA, R. *see* OKAMURA, N.
IWATA, R. *see* TASHIRO, M.

JÁRAY, J. *see* KÓBORI, L.
JÖNSSON, A.K. *see* WESTER, K.
JACKLIN, A. *see* DONYAI, P.
JACOB, P. III *see* HALLER, C.A.

JADA, S.R. *see* LAL, S.
JAEGER, R. *see* FOUNTAINE, R.
JAMBRECINA, A. *see* SCHWEDHELM, E.
JAMES, R. *see* ISBISTER, G.K.
JANG, I.-J. *see* KIM, B.-H.
JANMAHASATIAN, S., DUFFULL, S.B., CHAGNAC, A., KIRKPATRICK, C.M.J. & GREEN, B. Lean body mass normalizes the effect of obesity on renal function: 964
JANSEN, P.A.F. *see* KUIJPERS, M.A.J.
JEPSEN, P. *see* TØRRING, M.L.
JERLING, M. *see* OBUA, C.
JHAJ, R. *see* BALAKRISHNAN, S.
JIANG, B. *see* RAMBARAN, C.
JIANG, X., GALETTIS, P., LINKS, M., MITCHELL, P.L. & MCLACHLAN, A.J. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate: 326
JIAO, Z., DING, J.-J., SHEN, J., LIANG, H.-Q., ZHONG, L.-J., WANG, Y., ZHONG, M.-K. & LU, W.-Y. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9: 893
JIRASOMPRASERT, T. *see* LIMENTA, L.M.G.
JODRELL, D. *see* CAMIDGE, D.R.
JONES, L. *see* MCGETTIGAN, P.
JONVILLE-BÉRA, A.P., PAROUX, L. & AUTRET-LECA, E. Assessing general practitioners' prescribing behaviour in elderly patients with concealed renal failure: 961
JOSEPH-RIDGE, N. *see* KHOSRAVAN, R.
JUNG, D. *see* SCHWEDHELM, E.

KÓBORI, L., KÖHALMY, K., PORROGI, P., SÁRVÁRY, E., GERLEI, Z., FAZAKAS, J., NAGY, P., JÁRAY, J. & MONOSTORY, K. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism: 428
KØBER, L. *see* HANSEN, M.L.
KÖHALMY, K. *see* KÓBORI, L.
KÖHLER, G. *see* PETERSEN, A.H.
KÖLLING, P. *see* BAKKER, M.K.
KALLIOKOSKI, A., NEUVONEN, M., NEUVONEN, P.J. & NIEMI, M. No significant effect of *SLCO1B1* polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone: 78
KALRA, L. *see* RAMBARAN, C.
KARLSSON, M.O. *see* HAMRÉN, B.
KARNAD, D.R. *see* KULKARNI, U.P.
KARUNAJEEWA, H.A. *see* LAW, I.
KATO, M. *see* OKAMURA, N.
KATO, M. *see* TASHIRO, M.
KELLY, J.G. *see* TAN, K.M.
KEMME, M.J.B. *see* BROEYER, F.J.F.
KERWIN, R. *see* TAYLOR, D.
KEZOUH, A. *see* MIKAELOFF, Y.
KHOSRAVAN, R., GRABOWSKI, B., WU, J.-T., JOSEPH-RIDGE, N. & VERNILLET, L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects: 355
KIM, B.-H., LIM, H.-S., CHUNG, J.-Y., KIM, J.-R., LIM, K.S., SOHN, D.-R., CHO, J.-Y., YU, K.-S., SHIN, S.-G., PAICK, J.-S. & JANG, I.-J. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects: 848
KIM, J.-R. *see* KIM, B.-H.
KIPSHIDZE, N.N., FAREED, J., MOSES, J.W. & SERRUYS, P.W. REVIEWED BY FERRO, A. Textbook of Interventional Cardiovascular Pharmacology: 623
KIRKPATRICK, C.M.J. *see* HENNIG, S.
KIRKPATRICK, C.M.J. *see* JANMAHASATIAN, S.
KITAGAWA, J. *see* OHNO, T.
KLITGAARD, T. & NIELSEN, T.G. Overview of the human pharmacokinetics of recombinant activated factor VII: 3
KLUNGEL, O. *see* DE VRIES, F.
KOKKI, H., KUMPULAINEN, E., LAISALMI, M., SAVOLAINEN, J., RAUTIO, J. & LEHTONEN, M. Diclofenac readily penetrates the cerebrospinal fluid in children: 879
KOKWARO, G.O. *see* MUCHOHI, S.N.
KOLIOS, G. *see* DAMASKOS, D.
KONG, D.C.M. *see* SUDHAKARAN, S.
KONG, M.-C. *see* LAL, S.
KORSATKO, S. *see* PETERSEN, A.H.
KOTEGAWA, T. *see* IMAI, H.
KREDO, T. *see* MEHTA, U.
KRISTENSEN, J.H. *see* ILETT, K.F.
KRSKA, J. & AVERY, A.J. Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations: 386
KSHIRSAGAR, N.A. *see* KULKARNI, U.P.
KUIJPERS, M.A.J., VAN MARUM, R.J., EGBERTS, A.C.G. & JANSEN, P.A.F. Relationship between polypharmacy and underprescribing: 130
KUIPERS, E.J. *see* HUNFELD, N.G.
KULKARNI, U.P., SWAR, B.D., KARNAD, D.R., DAVIS, S., PATWARDHAN, A.M., KSHIRSAGAR, N.A. & GOGTAY, N.J. A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation: 787
KUMPULAINEN, E. *see* KOKKI, H.

LÄER, S. *see* ALBERS, S.
LABADIE, R. *see* ANDREWS, E.
LABADIE, R. *see* DAMLE, B.
LADEMANN, J. *see* OTBERG, N.
LAISALMI, M. *see* KOKKI, H.
LAL, S., SANDANARAJ, E., JADA, S.R., KONG, M.-C., LEE, L.-H., GOH, B.-C., LEE, S.-C. & CHOWBAY, B. Influence of *APOE* genotypes and *VKORC1* haplotypes on warfarin dose requirements in Asian patients: 260
LAMMERS, J.-W. *see* DE VRIES, F.
LANDOWSKI, J. *see* CUBAŁA, W.J.
LANGHENDRIES, J.-P. *see* HIRT, D.
LANGLEY, S.J. *see* BORRILL, Z.L.
LARSSON, H. *see* WIDÉ, K.
LASTRA, C.F. *see* FERNÁNDEZ-LIZ, E.
LAURIDSEN, T.G. *see* VASE, H.
LAURSEN, T. *see* PETERSEN, A.H.
LAW, I., ILETT, K.F., HACKETT, L.P., PAGE-SHARP, M., BAIWOG, F., GOMORRAI, S., MUELLER, I., KARUNAJEEWA, H.A. & DAVIS, T.M.E. Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers: 674

LEBRANCHU, Y. *see* TERNANT, D.
LEE, L.-H. *see* LAL, S.
LEE, S.-C. *see* LAL, S.
LEHTONEN, M. *see* KOKKI, H.
LEMIÈRE, C. *see* CYR, M.-C.
LENDERS, J.W.M. *see* BRAAM, R.L.
LEROY, E. *see* WANG, Y.
LEUFKENS, H. *see* DE VRIES, F.
LEUFKENS, H.G.M. *see* VAN LUIJN, J.C.F.
LEWIS, L.D. *see* ARONSON, J.K.
LI, J. *see* SUDHAKARAN, S.
LIANG, H.-Q. *see* JIAO, Z.
LIGUEROS-SAYLAN, M. *see* HE, Y.-L.
LIM, H.-S. *see* KIM, B.-H.
LIM, K.S. *see* KIM, B.-H.
LIMENTA, L.M.G., JIRASOMPRASERT, T., TANKANITLERT, J., SVASTI, S., WILAIRAT, P., CHANTHARAKSRI, U., FUCHAROEN, S. & MORALES, N.P. UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers: 908
LIN, Z. *see* QUINNEY, S.K.
LINDQUIST, M. *see* STRANDELL, J.
LINKS, M. *see* JIANG, X.
LINSCHEID, M. *see* OTBERG, N.
LIU, H.-L. *see* SUN, H.
LIU, Y.-Z. *see* SUN, H.
LIU, Z.-Q. *see* SUN, H.
LOH, M.T. *see* PAN, A.X.
LOKE, Y.K. *see* HOLLAND, R.
LOKIEC, F. *see* BRAIN, E.G.C.
LU, W.-Y. *see* JIAO, Z.
LUIJENDIJK, H.J., TIEMEIER, H., HOFMAN, A., HEERINGA, J. & STRICKER, B.H. CH. Determinants of chronic benzodiazepine use in the elderly: A longitudinal study: 593
LUKACS, Z. *see* SCHWEDHELM, E.

MAAS, R. *see* BIEREND, A.
MAAS, R. *see* SCHWEDHELM, E.
MACDONALD, T.M. & MORANT, S.V. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom: 775
MACDONALD, T.M. *see* MURPHY, M.J.
MADSEN, M. *see* HANSEN, M.L.
MAESTRONI, G.J., OTSA, K. & CUTOLO, M. Melatonin treatment does not improve rheumatoid arthritis: 797
MAITRA, A. *see* SINGH, N.
MALMQVIST, U. *see* PETTERSSON, J.
MAO, G.G. *see* QIU, F.R.
MARGUGLIO, A. *see* HIRT, D.
MARIÑO, E.L. *see* FERNÁNDEZ-LIZ, E.
MARUYAMA, M. *see* OKAMURA, N.
MASUDA, Y. *see* OHNO, T.
MATHOT, R.A. *see* HUNFELD, N.G.
MAULIDI, H., GODAMBE, S. & CHOW, P. Suspected drug reaction with piperacillin/tazobactam, in a premature infant: 971
MAUTNER, A. *see* PETERSEN, A.H.
MAZHAR, S.H.R., ISMAIL, N.E., NEWTON, D.A.G. & CHRYSTYN, H. Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation: 334
MCGARRY, K. *see* TAN, K.M.
MCGETTIGAN, P., HAN, P., JONES, L., WHITAKER, D. & HENRY, D. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases: 927
MCLACHLAN, A.J. *see* JIANG, X.
MCMAHON, C.J. *see* GUEORGUIEVA, I.
MEGURO, K. *see* OKAMURA, N.
MEHTA, U., DURRHEIM, D.N., BLOCKMAN, M., KREDO, T., GOUNDEN, R. & BARNES, K.I. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study: 396
MEIBOHM, B. *see* ALBERS, S.
MENON, P.A. *see* BAKSHI, S.
MENTRÉ, F. *see* HIRT, D.
MERLINO, L. *see* CORRAO, G.
MIKAELOFF, Y., KEZOUH, A. & SUISSA, S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease: 203
MILLER, M. *see* ISBISTER, G.K.
MILNE, R.W. *see* DAVIES, B.J.
MILTON, A. *see* FOUNTAINE, R.
MINASIAN, L. *see* HUSSEIN, O.
MINERS, J.O. *see* POLASEK, T.M.
MIR, O. *see* TRAN, A.
MIR, T.S. & *see* ALBERS, S.
MISHRA, T.K. *see* GUPTA, P.
MITCHELL, M. *see* WIFFEN, P.
MITCHELL, P.L. *see* JIANG, X.
MIURA, M. *see* TATEISHI, T.
MIWA, T. *see* UMENO, K.
MIYABE, H. *see* OHNO, T.
MIYAKE, M. *see* TASHIRO, M.
MIYATA, Y. *see* OHNO, T.
MIZUSHIMA, Y. *see* BROEYER, F.J.F.
MODAMIO, P. *see* FERNÁNDEZ-LIZ, E.
MOLOKWU, C.N., SANDIFORD, N. & ANOSIKE, C. Safe prescribing by junior doctors: 615
MONOSTORY, K. *see* KÓBORI, L.
MONTASTRUC, J.L. *see* BÜRKI, F.
MORALES, N.P. *see* LIMENTA, L.M.G.
MORANT, S.V. *see* MACDONALD, T.M.
MORICE, A.H. *see* RAMSAY, J.
MORIMOTO, T. *see* IMAI, H.
MOROKUMA, S. *see* TSUKIMORI, K.
MORTIMER, K.J. *see* WHALE, C.I.
MOSES, J.W. *see* KIPSHIDZE, N.N.
MOULD, D.R. *see* CRONENBERGER, C.
MUCHMORE, D.B. *see* PAN, A.X.
MUCHOHI, S.N. OBIERO, K. NEWTON, C.R.J.C. OGUTU, B.R. EDWARDS, G. & KOKWARO, G.O. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions: 12
MUELLER, I. *see* LAW, I.
MULDER, P.G. *see* HUNFELD, N.G.
MURPHY, M.J., WEI, L., WATSON, A.D. & MACDONALD, T.M. 'Real-life' reduction in cholesterol with statins, 1993 to 2002: 587
MUTA, K. *see* TSUKIMORI, K.
MWINYI, J. *see* BALDWIN, R.M.
MYRBERG, O. *see* OHLSSON, S.

NAGASHIMA, Y. *see* UMENO, K.
NAGY, P. *see* KÓBORI, L.
NAKADE, S. *see* OHNO, T.
NAKANO, S. *see* FUJIMURA, A.
NAKANO, S. *see* IMAI, H.
NAKAYAMA, K. *see* OHNO, T.
NAPPI, R.E. *see* CORRAO, G.
NARENDRAN, G. *see* BAKSHI, S.
NATION, R.L. *see* SUDHAKARAN, S.
NEUVONEN, M. *see* KALLIOKOSKI, A.
NEUVONEN, P.J. *see* KALLIOKOSKI, A.
NEWTON, C.R.J.C. *see* MUCHOHI, S.N.
NEWTON, D.A.G. *see* MAZHAR, S.H.R.
NICOTRA, F. *see* CORRAO, G.

NIELSEN, J.C. *see* HE, Y.-L.
NIELSEN, T.G. *see* KLITGAARD, T.
NIEMI, M. *see* KALLIOKOSKI, A.
NISHIJO, H. *see* UMENO, K.
NORRIS, R. *see* HENNIG, S.
NTALE, M. *see* OBUA, C.
NUSSEY, F. *see* CAMIDGE, D.R.

O'GRADY, K. *see* DONYAI, P.
O'LEARY, M. *see* ISBISTER, G.K.
OBACH, R.S. *see* YOUDIM, K.A.
OBIERO, K. *see* MUCHOHI, S.N.
OBUA, C., HELLGREN, U., NTALE, M., GUSTAFSSON, L.L., OGWAL-OKENG, J.W., GORDI, T. & JERLING, M. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen: 493
OGUTU, B.R. *see* MUCHOHI, S.N.
OGWAL-OKENG, J.W. *see* OBUA, C.
OHASHI, K. *see* IMAI, H.
OHLSSON, S. *see* BALDWIN, R.M.
OHLSSON, S., HOLM, L., MYRBERG, O., SUNDSTRÖM, A. & YUE, Q.-Y. Noscapine may increase the effect of warfarin: 277
OHNO, T., NAKADE, S., NAKAYAMA, K., KITAGAWA, J., UEDA, S., MIYABE, H., MASUDA, Y. & MIYATA, Y. Absolute bioavailability of imidafenacin after oral administration to healthy subjects: 197
OHRESSER, M. *see* TERNANT, D.
OKAMURA, N., FUNAKI, Y., TASHIRO, M., KATO, M., ISHIKAWA, Y., MARUYAMA, M., ISHIKAWA, H., MEGURO, K., IWATA, R. & YANAI, K. *In vivo* visualization of donepezil binding in the brain of patients with Alzheimer's disease: 472
OLIVER, J.J. *see* CAMIDGE, D.R.
ONO, T. *see* UMENO, K.
OTBERG, N., PATZELT, A., RASULEV, U., HAGEMEISTER, T., LINSCHEID, M., SINKGRAVEN, R., STERRY, W. & LADEMANN, J. The role of hair follicles in the percutaneous absorption of caffeine: 488
OTSA, K. *see* MAESTRONI, G.J.
OVERMEIRE, B.V. *see* HIRT, D.

PADMAPRIYADARSINI, C. *see* BAKSHI, S.
PAECH, M.J. *see* ILETT, K.F.
PAGE-SHARP, M. *see* ILETT, K.F.
PAGE-SHARP, M. *see* LAW, I.
PAICK, J.-S. *see* KIM, B.-H.
PAINTAUD, G. *see* TERNANT, D.
PAN, A.X., DE LA PEÑA, A., YEO, K.P., CHAN, C., LOH, M.T., WISE, S.D., SILVERMAN, B.L. & MUCHMORE, D.B. Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR® inhaled insulin pharmacokinetics and glucodynamics: 480
PARIS, A., GONNET, N., CHAUSSARD, C., BELON, P., ROCOURT, F., SARAGAGLIA, D. & CRACOWSKI, J.L. Effect of homeopathy on analgesic intake following knee ligament reconstruction: a phase III monocentre randomized placebo controlled study: 180
PAROUX, L. *see* JONVILLE-BÉRA, A.P.
PATEL, Z. *see* SINGH, N.
PATON, C. *see* TAYLOR, D.
PATWARDHAN, A.M. *see* KULKARNI, U.P.
PATZELT, A. *see* OTBERG, N.
PAULI, G. *see* FROSSARD, N.
PEDERSEN, E.B. *see* VASE, H.
PEDERSEN, R.S. *see* BALDWIN, R.M.
PERSSON, P. *see* PETTERSSON, J.
PETERS, A.M. *see* RUPARELIA, P.
PETERSEN, A.H., KÖHLER, G., KORSATKO, S., WUTTE, A., WONISCH, M., MAUTNER, A., RØNN, B.B., CLAUSON, P., LAURSEN, T., WOLLMER, P. & PIEBER, T.R. The effect of exercise on the absorption of inhaled human insulin in healthy volunteers: 165
PETERSON, C. *see* HAGLUND, S.
PETERSON, G.M. *see* REEVE, J.F.
PETTERSSON, J., HINDORF, U., PERSSON, P., BENGTSSON, T., MALMQVIST, U., WERKSTRÖM, V. & EKELUND, M. Muscular exercise can cause highly pathological liver function tests in healthy men: 253
PHAM, V.V., STICHTENOTH, D.O. & BORLAK, J. Graft rejection: pharmacogenetic analysis or drug anamnesis?: 959

PHILLIPS, J.S. & PRINSLEY, P.R. Prescribing practices for Betahistine: 470
PHIPPS, A. *see* YOUDIM, K.A.
PICHLER, W.J. Drug hypersensitivity: 447
PIDGEON, S. Wiley Handbook of Current and Emerging Drug Therapies: 449
PIEBER, T.R. *see* PETERSEN, A.H.
PITSOUNI, E.I. *see* FALAGAS, M.E.
PLOWCHALK, D.R. *see* YOUDIM, K.A.
POLASEK, T.M. & MINERS, J.O. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants: 87
PONS, G. *see* TRAN, A.
PORROGI, P. *see* KÓBORI, L.
POSTMA, M.J. *see* BOERSMA, C.
POULSEN, H.E. *see* GLINTBORG, B.
POUWELS, S. *see* DE VRIES, F.
PRINSLEY, P.R. *see* PHILLIPS, J.S.
PRUGNAUD, J.-L. Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework: 619
PUROHIT, A. *see* FROSSARD, N.

QIU, F.R., WANG, G.J., ZHAO, Y.N., SUN, H., MAO, G.G., A, J.Y. & SUN, J. Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers: 270
QUINNEY, S.K., HAEHNER, B.D., RHOADES, M.B., LIN, Z., GORSKI, J.C. & HALL, S.D. Interaction between midazolam and clarithromycin in the elderly: 98

RØNN, B.B. *see* PETERSEN, A.H.
RØNNING, M. *see* ENGELAND, A.
RAJASEKARAN, S. *see* BAKSHI, S.
RAJENDRAN, S.D. *see* ARULMANI, R.
RAMACHANDRAN, G. *see* BAKSHI, S.
RAMASAMY, S. *see* ISBISTER, G.K.
RAMBARAN, C., JIANG, B., RITTER, J.M., SHAH, A., KALRA, L. & CHOWIENCZYK, P.J. Assessment of endothelial function: comparison of the pulse wave response to β_2-adrenoceptor stimulation with flow mediated dilatation: 238
RAMESH, K. *see* BAKSHI, S.
RAMSAY, J., WRIGHT, C., THOMPSON, R., HULL, D. & MORICE, A.H.

Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective *vs.* subjective measures: 737
RASMUSSEN, S. *see* HANSEN, M.L.
RASULEV, U. *see* OTBERG, N.
RAU, T. *see* BIEREND, A.
RAUTIO, J. *see* KOKKI, H.
RAYNER, C.R. *see* SUDHAKARAN, S.
REEVE, J.F., TENNI, P.C. & PETERSON, G.M. An electronic prompt in dispensing software to promote clinical interventions by community pharmacists: a randomized controlled trial: 377
REY, E. *see* HIRT, D.
REY, E. *see* TRAN, A.
REZAI, K. *see* BRAIN, E.G.C.
RHOADES, M.B. *see* QUINNEY, S.K.
RIIS, A. *see* TØRRING, M.L.
RITTER, J.M. Drug regulation & therapeutic efficacy: 801
RITTER, J.M. Editors' Report for 2007: 301
RITTER, J.M. Editors' view January 2008: 1
RITTER, J.M. Minimising Harm: Human Variation and Adverse Drug Reactions (ADRs): 451
RITTER, J.M. Pharmacokinetic(s) matters: stroke treatment *et cetera*: 299
RITTER, J.M. *see* RAMBARAN, C.
RITTER, J.M. Sensitivity: real (interferons, odorants) and imagined (homeopathy): 151
RIVIERE, G.-J. *see* HE, Y.-L.
RIVIERE, G.-J. *see* WANG, Y.
RIZZINI, P. *see* VELO, G.
ROCOURT, F. *see* PARIS, A.
RODRÍGUEZ, T. *see* FERNÁNDEZ-LIZ, E.
ROETHIG, H.-J. *see* CRONENBERGER, C.
ROSE, K. & VAN DEN ANKER, J.N. Guide to Paediatric Clinical Research: 282
ROSENBERG, M. *see* HE, Y.-L.
ROTHWELL, N.J. *see* GUEORGUIEVA, I.
ROWLAND, M. *see* GUEORGUIEVA, I.
ROY, V. *see* GUPTA, P.
RUPARELIA, P., CHEOW, H.K., EVANS, J.W., BANNEY, L., SHANKAR, S., SZCZEPURA, K.R., SWIFT, A.E., BALLINGER, J.R., HARTMAN, N.G., CHILVERS, E.R. & PETERS, A.M. Pulmonary elimination rate of inhaled ^{99m}Tc-sestamibi radioaerosol is delayed in healthy cigarette smokers: 611

SÁRVÁRY, E. *see* KÓBORI, L.
SØNDERGAARD, J. *see* TØRRING, M.L.
SØRENSEN, H.T. *see* TØRRING, M.L.
SABO, R. *see* HE, Y.-L.
SAHA, L. *see* GAUTAM, C.S.
SALAMON, R. *see* SALMI, L.R.
SALLUSTIO, B.C. *see* DAVIES, B.J.
SALMI, L.R., SUISSA, S., CHÊNE, G. & SALAMON, R. Clinically informative measures of the effect of drugs or other interventions: 935
SALMON, D. *see* HIRT, D.
SAMUELSSON, O. *see* HAMRÉN, B.
SANDANARAJ, E. *see* LAL, S.
SANDIFORD, N. *see* MOLOKWU, C.N.
SARAGAGLIA, D. *see* PARIS, A.
SARKAR, M. *see* CRONENBERGER, C.
SAVOLAINEN, J. *see* KOKKI, H.
SCARTH, S. *see* GUEORGUIEVA, I.
SCHEPENS, P. *see* HIRT, D.
SCHNEIDER, J.S. *see* ISBISTER, G.K.
SCHOEMAKER, H.C. *see* BROEYER, F.J.F.
SCHRAMM, T.K. *see* HANSEN, M.L.
SCHRAN, H. *see* WANG, Y.
SCHULZE, F. *see* SCHWEDHELM, E.
SCHWEDHELM, E. *see* BIEREND, A.
SCHWEDHELM, E., MAAS, R., FREESE, R., JUNG, D., LUKACS, Z., JAMBRECINA, A., SPICKLER, W., SCHULZE, F. & BÖGER, R.H. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism: 51
SCOTT, K.L. *see* ILETT, K.F.
SERRUYS, P.W. *see* KIPSHIDZE, N.N.
SETHI, G.R. *see* GUPTA, P.
SETHURAMAN, V. *see* WANG, Y.
SHAH, A. *see* RAMBARAN, C.
SHANKAR, S. *see* RUPARELIA, P.
SHEN, J. *see* JIAO, Z.
SHEN, Z.-X. *see* WANG, Y.
SHESTATSKI, K. *see* HUSSEIN, O.
SHIN, S.-G. *see* KIM, B.-H.
SHOJAKU, H. *see* UMENO, K.
SILVERMAN, B.L. *see* PAN, A.X.
SINGH, D. *see* BORRILL, Z.L.
SINGH, N., GOLANI, A., PATEL, Z. & MAITRA, A. Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis: 418
SINKGRAVEN, R. *see* OTBERG, N.
SKINNER, C. *see* CAMIDGE, D.R.
SKINNER, C. *see* CURRIE, G.P.
SKURTVEIT, S. *see* ENGELAND, A.
SNELLING, M. *see* WIFFEN, P.
SOENDERGAARD, B. *see* AAGAARD, L.
SOHN, D.-R. *see* KIM, B.-H.
SOLOMON, L. *see* HUSSEIN, O.
SOMOGYI, A.A. *see* DAVIES, B.J.
SOVANI, M.P. *see* WHALE, C.I.
SPEIDL, S. *see* TOTHFALUSI, L.
SPICKLER, W. *see* SCHWEDHELM, E.
SPIGSET, O. *see* WESTER, K.
STENVER, D.I. *see* AAGAARD, L.
STERRY, W. *see* OTBERG, N.
STICHTENOTH, D.O. *see* PHAM, V.V.
STOLAR, M. *see* FOUNTAINE, R.
STOLK, P. *see* VAN LUIJN, J.C.F.
STONER, N. *see* WIFFEN, P.
STRANDELL, J., BATE, A., LINDQUIST, M. & EDWARDS, I.R. Drug–drug interactions – a preventable patient safety issue?: 144
STRICKER, B.H. *see* LUIJENDIJK, H.J.
STRICKER, B.H.CH. *see* BIJL, M.J.
STROLIN-BENEDETTI, M. *see* FROSSARD, N.
SUDHAKARAN, S., RAYNER, C.R., LI, J., KONG, D.C.M., GUDE, N.M. & NATION, R.L. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus: 667
SUGIMOTO, K., UNO, T., YAMAZAKI, H. & TATEISHI, T. Limited frequency of the *CYP2C19*17* allele and its minor role in a Japanese population: 437
SUISSA, S. *see* MIKAELOFF, Y.
SUISSA, S. *see* SALMI, L.R.
SUN, H. *see* QIU, F.R.
SUN, H., GONG, Z.-C., YIN, J.-Y., LIU, H.-L., LIU, Y.-Z., GUO, Z.-W., ZHOU, H.-H., WU, J. & LIU, Z.-Q. The association of adiponectin allele *45T/G* and *−11377C/G* polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients: 917
SUN, J. *see* QIU, F.R.

SUNDSTRÖM, A. *see* OHLSSON, S.
SURESH, B. *see* ARULMANI, R.
SUZUKI, J. *see* BROEYER, F.J.F.
SUZUKI, T. *see* TATEISHI, T.
SUZUKI, T. *see* UMENO, K.
SVASTI, S. *see* LIMENTA, L.M.G.
SWAMINATHAN, S. *see* BAKSHI, S.
SWAR, B.D. *see* KULKARNI, U.P.
SWIFT, A.E. *see* RUPARELIA, P.
SY, S.K. *see* ILETT, K.F.
SZCZEPURA, K.R. *see* RUPARELIA, P.

TØRRING, M.L., RIIS, A., CHRISTENSEN, S., THOMSEN, R.W., JEPSEN, P., SØNDERGAARD, J. & SØRENSEN, H.T. Perforated peptic ulcer and short-term mortality among tramadol users: 565
TAIPALENSUU, J. *see* HAGLUND, S.
TAL-SINGER, R. *see* BORRILL, Z.L.
TAN, K.M., KELLY, J.G. & MCGARRY, K. Statins and phenytoin interact – a case history: 147
TANKANITLERT, J. *see* LIMENTA, L.M.G.
TASHIRO, M. *see* OKAMURA, N.
TASHIRO, M., DUAN, X., KATO, M., MIYAKE, M., WATANUKI, S., ISHIKAWA, Y., FUNAKI, Y., IWATA, R., ITOH, M. & YANAI, K. Brain histamine H_1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with ^{11}C-doxepin: 811
TATEISHI, T. *see* SUGIMOTO, K.
TATEISHI, T., MIURA, M., SUZUKI, T. & UNO, T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers: 693
TATTERSFIELD, A.E. *see* WHALE, C.I.
TAYLOR, D., PATON, C. & KERWIN, R. REVIEWED BY JACOBS, G.E. & COHEN, F. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, 9th Edition: 624
TEETER, J. *see* FOUNTAINE, R.
TENNI, P.C. *see* REEVE, J.F.
TERNANT, D., BÜCHLER, M., BÉNÉTON, M., ALVÁN, G., OHRESSER, M., TOUCHARD, G., DE LIGNY, B.H., TOUPANCE, O., WATIER, H., LEBRANCHU, Y. & PAINTAUD, G. Interindividual variability in the concentration–effect relationship of antilymphocyte globulins – a possible influence of FcγRIIIa genetic polymorphism: 60
THIEN, T. *see* BRAAM, R.L.
THOMPSON, R. *see* RAMSAY, J.
THOMSEN, R.W. *see* TØRRING, M.L.
TIEMEIER, H. *see* LUIJENDIJK, H.J.
TOAL, C.B. *see* BROWN, M.J.
TORP-PEDERSEN, C. *see* HANSEN, M.L.
TOTHFALUSI, L., SPEIDL, S. & ENDRENYI, L. Exposure–response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets: 110
TOUCHARD, G. *see* TERNANT, D.
TOUPANCE, O. *see* TERNANT, D.
TOURNAMILLE, J.-F. *see* BLASCO, H.
TOUW, D.J. *see* HUNFELD, N.G.
TRÉLUYER, J.-M. *see* HIRT, D.
TRÉLUYER, J.-M. *see* TRAN, A.
TRAN, A. *see* HIRT, D.
TRAN, A., BOURNERIAS, F., BELLER, C.L., MIR, O., REY, E., PONS, G., DELAHOUSSE, M. & TRÉLUYER, J.-M. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms: 279
TRELUYER, J.-M. *see* HIRT, D.
TREUHERZ, F. Comment on 'The truth about homeopathy' by Ernst: 281
TSUBOTA, M. *see* UMENO, K.
TSUKIMORI, K., MOROKUMA, S., YOSHIMURA, T., MUTA, K. & WAKE, N. Neutropenia induced in a patient by treatment with ritodrine: *in vitro* evaluation of myeloid progenitor colony-forming cells: 149
TSUTSUMI, K. *see* IMAI, H.
TURGEON, J. *see* ZAKRZEWSKI-JAKUBIAK, M.
TYRELL, P.J. *see* GUEORGUIEVA, I.

UEDA, S. *see* OHNO, T.
UMENO, K., HORI, E., TSUBOTA, M., SHOJAKU, H., MIWA, T., NAGASHIMA, Y., YADA, Y., SUZUKI, T., ONO, T. & NISHIJO, H. Effects of direct Cedrol inhalation into the lower airway on autonomic nervous activity in totally laryngectomized subjects: 188
UNO, T. *see* SUGIMOTO, K.
UNO, T. *see* TATEISHI, T.
URIEN, S. *see* BRAIN, E.G.C.
URIEN, S. *see* HIRT, D.

VAN AKEN, B.E. *see* BROEYER, F.J.F.
VAN DEN ANKER, J.N. *see* ROSE, K.
VAN DEN BERG, P.B. *see* BAKKER, M.K.
VAN DEN BERG, P.B. *see* VROOM, F.
VAN DER GRAAF, F. *see* HOUGARDY, D.M.C.
VAN GELDER, T. *see* BIJL, M.J.
VAN LUIJN, J.C.F., STOLK, P., GRIBNAU, F.W.J. & LEUFKENS, H.G.M. Gap in publication of comparative information on new medicines: 716
VAN MARUM, R.J. *see* KUIJPERS, M.A.J.
VAN SCHAIK, R.H. *see* HUNFELD, N.G.
VAN SCHAIK, R.H.N. *see* BIJL, M.J.
VAN STAA, T. *see* DE VRIES, F.
VAN UUM, S.H.M. *see* BRAAM, R.L.
VASE, H., LAURIDSEN, T.G., BECH, J.N. & PEDERSEN, E.B. Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans: 822
VELO, G. & RIZZINI, P. Erice statement on drug innovation: 440
VERNILLET, L. *see* KHOSRAVAN, R.
VESSEY, S.R. *see* BORRILL, Z.L.
VISSER, L.E. *see* BIJL, M.J.
VISSER, S.T. *see* BOERSMA, C.
VROOM, F., VAN DEN BERG, P.B. & DE JONG-VAN DEN BERG, L.T.W. Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful?: 275
VULTO, A.G. *see* BIJL, M.J.

WAKE, N. *see* TSUKIMORI, K.
WANG, G.J. *see* QIU, F.R.
WANG, Y. *see* HE, Y.-L.
WANG, Y. *see* JIAO, Z.
WANG, Y., ZHOU, L., DUTREIX, C., LEROY, E., YIN, Q., SETHURAMAN, V., RIVIERE, G.-J., YIN, O.Q.P., SCHRAN, H. & SHEN, Z.-X. Effects of imatinib (Glivec) on the

pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia: 885
WATANUKI, S. *see* TASHIRO, M.
WATIER, H. *see* TERNANT, D.
WATSON, A.D. *see* MURPHY, M.J.
WEBB, D.J. *see* CAMIDGE, D.R.
WEI, G. *see* FOUNTAINE, R.
WEI, L. *see* MURPHY, M.J.
WEIHE, P. *see* HALLING, J.
WERKSTRÖM, V. *see* PETTERSSON, J.
WESTER, K., JÖNSSON, A.K., SPIGSET, O., DRUID, H. & HÄGG, S. Incidence of fatal adverse drug reactions: a population based study: 573
WHALE, C.I., SOVANI, M.P., MORTIMER, K.J., HARRISON, T.W. & TATTERSFIELD, A.E. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose–response study: 841
WHITAKER, D. *see* MCGETTIGAN, P.
WHITE, M. *see* ZAKRZEWSKI-JAKUBIAK, M.
WICHOWICZ, H.M. *see* CUBAŁA, W.J.
WIDE, K., LARSSON, H., BERTILSSON, L. & DICZFALUSY, U. Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy: 708
WIFFEN, P., MITCHELL, M., SNELLING, M. & STONER, N.; REVIEWED BY GUCHELAAR, H.-J. The Oxford Handbook of Clinical Pharmacy: 799
WILAIRAT, P. *see* LIMENTA, L.M.G.
WISE, S.D. *see* PAN, A.X.
WOLLMER, P. *see* PETERSEN, A.H.
WONISCH, M. *see* PETERSEN, A.H.
WRIGHT, C. *see* RAMSAY, J.
WRIGHT, D. *see* HOLLAND, R.
WU, J. *see* SUN, H.
WU, J.-T. *see* KHOSRAVAN, R.
WUTTE, A. *see* PETERSEN, A.H.

YADA, Y. *see* UMENO, K.
YAMAZAKI, H. *see* SUGIMOTO, K.
YANAI, K. *see* OKAMURA, N.
YANAI, K. *see* TASHIRO, M.
YASUHARA, H. *see* FUJIMURA, A.
YEO, K.P. *see* PAN, A.X.
YIN, J.-Y. *see* SUN, H.
YIN, O.Q.P. *see* WANG, Y.
YIN, Q. *see* WANG, Y.
YOSHIMURA, T. *see* TSUKIMORI, K.
YOUDIM, K.A., ZAYED, A., DICKINS, M., HIPPS, A., GRIFFITHS, M., DAREKAR, A., HYLAND, R., FAHMI, O., HURST, S., PLOWCHALK, D.R., COOK, J., GUO, F. & OBACH, R.S. Application of CYP3A4 *in vitro* data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction: 680
YU, K.-S. *see* KIM, B.-H.
YUE, Q.-Y. *see* OHLSSON, S.

ZAKRZEWSKI-JAKUBIAK, M., DE DENUS, S., DUBÉ, M.-P., BÉLANGER, F., WHITE, M. & TURGEON, J. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure: 742
ZAMBON, A. *see* CORRAO, G.
ZAYED, A. *see* YOUDIM, K.A.
ZHAO, Y.N. *see* QIU, F.R.
ZHONG, L.-J. *see* JIAO, Z.
ZHONG, M.-K. *see* JIAO, Z.
ZHOU, H.-H. *see* SUN, H.
ZHOU, L. *see* WANG, Y.
ZIDAN, J. *see* HUSSEIN, O.

BJCP British Journal of Clinical Pharmacology

DOI:10.1111/j.1365-2125.2008.03211.x

SUBJECT INDEX

This index was compiled from the keywords

4β-hydroxycholesterol, 708
5-hydroxyomeprazole, 767
6-mercaptopurine, 69
^{99m}Tc-sestamibi, 611
absorption rate metrics, 110
ACE inhibitors, 217
ACE, 742
acetylcholinesterase, 472
acute myocardial infarction, 217, 955
acute re-exposure, 480
acyl glucuronide, 855
adiponectin, 917
administration, 165
administrative database, 40
ADP receptors, 540
adverse drug reactions, 210, 364, 396, 573
adverse effects, 22
aerosol, 165, 611
age, 338, 407
albuminuria, 723
alkylating agents, 607
allergen, 172
Alzheimer's disease, 472
amitriptyline, 134
analgesia, 180
angiotensin II type 1 receptor blockers, 822
angiotensin, 742
antacid, 355
antibiotic, 942
antidepressants, 558
antihistamine, 172
anti-inflammatory agents, 565
antilymphocyte serum, 60
antimicrobial agent, 942
antitussive, 737
antivenom, 139
apolipoproteinE, 260
arachnidism, 139
Asian, 260
aspirin, 540
asymmetric dimethylarginine, 51
azathioprine, 69

β_2-agonists, 841
β-agonists, 580
baculosomes, 680
benzodiazepine use, 593
beta-androceptor, 238
bias, 942
bioavailability, 197
bioequivalence, 110
bleeding rate, 3
bleeding time, 761
blood pressure, 188, 723, 822
body mass index, 338
body plethysmography, 244
bone fracture, 123
bromide, 733

C-11377G polymorphism, 917
caffeine, 488, 833
cancer, 224
carbamazepine, 110, 708
carboxyhaemoglobin, 30
cardiovascular diseases, 723
carvedilol, 511
case-control, 203
cerebrospinal fluid, 879
chemotherapy, 326
chest pain, 580
child, 879
children, 12, 423
chloroquine, 493, 674
cholesterol, 775
chronic obstructive pulmonary disease, 611, 803
clarithromycin, 98
clinical interventions, 377
clinical trial results database, 716
clinical trials, 253
CML, 885
cohort studies, 935
cohort study, 40, 593
combined, 531
community pharmacy services, 386
comparative information, 716
compliance, 871
computer simulation, 511
confounding factors (epidemiology), 580
congestive heart failure, 927
contraceptives, 531
convulsions, 12
COPD, 40, 244, 841
cord/maternal distribution, 674
coronary artery disease, 540
coronary heart disease, 587
cost, 210, 407
cough, 737
crossover trial, 646
cross-sectional studies, 775
CSF, 317
CYP 3A4,5,7, 959
CYP1A2, 270
CYP2C19 polymorphlsm, 752
*CYP2C19*17* mutation, 752
*CYP2C19*2* mutation, 752
CYP2C19, 437, 548
CYP2D6 polymorphism, 134
CYP2D6, 347, 558, 885
CYP3A, 98, 701
CYP3A4, 680, 708
CYP3A5, 708
cystic fibrosis, 502
cytochrome P450, 98, 428, 680, 959
cytochromes P450, 87

danshen extract, 270
database, 123
decision support, 377
deferiprone, 908
depression, 767
desethylchloroquine, 674
desloratadine, 172
dextromethorphan, 737
dFdU, 326
diclofenac, 879
dietary supplement, 833
diplotype, 917
donepezil, 472
dose–response, 60
drug adherence, 733
drug development, 716
drug interaction, 270
drug metabolism, 607
drug metabolizing capacity, 428
drug safety, 165
drug treatment, 217
drug use, 407, 653
drug utilization, 600
drug-drug interactions, 680

© 2008 Blackwell Publishing Ltd

drug-induced toxicity, 428
drug-related morbidity, 396

efavirenz, 523
effectiveness, 587
elderly, 98, 130, 593
electronic prescribing, 230
enantiomer, 693
enantioselective, 347
endothelial function, 238
enterohepatic circulation, 893
envenoming, 139
enzyme induction, 701
epidemiology, 573
epilepsy, 708
equivalence trials, 955
ergogenic, 833
ethics,methodology, 955
evaluation studies, 935
exacerbation, 334
exacerbations, 40
exercise, 833
exposure rate, 600
ezetimibe, 637

falciparum malaria, 493
Faroe Islands, 134
febuxostat, 355
fexofenadine, 693
first-generation antihistamine, 811
flow mediated dilatation, 238
flow-mediated vasodilation, 51
follicular penetration, 488
food, 355
formoterol, 841
formulation, 646
free radicals, 22
FTC, 30

gemcitabine, 326
gender, 338, 407
genetic polymorphism, 437
Glivec, 885
glomerular filtration rate, 822
glucodynamics, 480
GPRD, 203

hair follicle, 488
heart failure, 742
heart rate, 188
histamine H1 receptor occupancy, 811
HIV protease inhibitors, 667
HIV, 548
HIV/AIDS, 396
home visits, 265
homeopathy, 180
hormone replacement therapy, 123
hospitalisation, 396
HPLC, 418
human, 197, 767
hypercholesterolaemia, 637, 775
hypertension, 733, 775

ibuprofen, 629
ifosfamide, 607
IgG receptors, 60
imatinib,metoprolol, 885
IMPDH, 69
impulse oscillometry, 244
increased dose proposal, 493
indinavir, 667
infant dose, 661, 674
infant wellbeing, 661
infant, 879
inflammatory bowel disease, 69, 453
inhalation, 165
inhaled human insulin, 864
inhaled insulin, 480
inosine-5′-monophosphate dehydrogenase, 69
inpatients, 210
interconversion, 855
interleukin-1 receptor antagonist, 317
international normalized ratio, 787
intragastric pH, 752
intramuscular administration, 139
intravenous, 197
iron, 908
ischemia, 317
isoniazid, 418
itraconazole, 693

Japanese, 437

ketoconazole, 680
kidney transplantation, 60
knee ligament reconstruction, 180
knowledge, 364

L1, 908
L-arginine, 51
Latrodectus, 139
L-citrulline, 51
LDL oxidation, 637
levocetirizine, 172
lipid-lowering treatment, 587
liver function tests, 253
liver-graft, 428
long-acting bronchodilators, 244
lorazepam, 12
low dose, 423
lung, 165
lungs, 611

malaria, 12
mechanism-based inactivation, 87
mechanistic modelling, 855
medical birth registry, 653
medication lists, 265
medication review,meta-analysis, 303
metabolism, 326
microflora, 453
midazolam, 98
milk to plasma ratio, 418
milk, 674
mixed-effect model, 110
modelling, 317
mortality, 565, 573
mycophenolic acid, 893
myocardial infarction, 580
myocardial ischaemia, 580

natriuresis, 822
nebulizer, 334
nelfinavir, 548
nested case-control, 123
NICE, 224
nicotine replacement therapy, 480
nifedipine, 646
nitric oxide, 51
non-inferiority trials, 955
NONMEM, 548, 855
non-steroidal anti-inflammatory agents, 879
nonsteroidal, 565
nortriptyline, 87, 134
NovoSeven®, 3
NSAIDs, 203, 927

OATP1B1, 78
omeprazole sulphone, 767
oral, 197, 531
oxaliplatin, 326
oxidative stress, 22
oxybutynin, 871

paediatrics, 502, 511
pain, 180
pantoprazole, 767
parasympathetic activity, 188
paroxetine, 761
passive smoking, 864

patent ductus arteriosus, 629
patients, 317
PC-SOD, 22
penetration pathways, 488
Peptic ulcer perforation, 565
perhexiline, 347
P-glycoprotein, 611, 667, 693
pharmaceutical care, 386
pharmacist, 210, 303, 377
pharmacodynamics, 165, 338, 355, 607
pharmacoepidemiology, 364, 653
pharmacogenetic, 767
pharmacogenetics, 60, 78, 540, 558, 752
pharmacokinetics, 3, 12, 22, 60, 78, 165, 172, 197, 317, 326, 338, 347, 355, 423, 480, 511, 523, 531, 548, 607, 767, 848, 864, 871, 879, 885, 908
pharmacology, 833
pharmacovigilance, 396
pharmacy data, 653
pharmacy records, 265
pharma-epidemiology, 927
Phase II/ III clinical trials, 364
phosphodiesterase 4 inhibitors,management, 803
phosphodiesterase type 5 inhibitor, 848
physical exercise, 253
pioglitazone, 78
PK and PD sensitivities, 110
PK–PD relationship, 110
placebo-controlled crossover study design, 811
placental transfer, 667
plasma clearance rate, 3
platelet aggregation, 540, 637, 761
polymorphism, 558, 959
polymorphisms, 742
polypharmacy, 130
poor-metabolizer phenotype, 428
population, 607
population based study, 573
population-based prevalence, 775
population cholesterol, 587
population pharmacokinetics, 30, 493, 502, 629, 855, 893
positron emission tomography, 811
positron emission tomography (PET), 472
prebiotics, 453
pregnancy, 600, 653
prescribing errors, 230
prescription database, 653
prevalence, 407
prevention, 723
primary care, 386
primary health care, 407
probiotics, 453
prognosis, 224
proton pump inhibitors, 752
publication time-lag, 716
pulse wave analysis, 238
pyrazinamide, 423

RAAS, 742
rac-O-desmethyltramadol, 661
rac-tramadol, 661
randomized active-control trial, 716
randomized clinical trials, 935
recombinant activated factor VIIa, 3
record linkage, 123
recovery time course, 701
reflex, 822
registrations files, 364
relationship, 60
relative lung deposition, 334
renin, 742
resource allocation, 224
risperidone, 871
rosiglitazone efficacy, 917
rosiglitazone, 78

safety, 848
salbutamol, 580
Scottish Medicines Consortium, 224
secondary medication interviews, 265
secondary prevention, 217
second-generation antihistamine, 811
selective serotonin reuptake inhibitors, 600
serotonin transporter polymorphism, 761
severity, 210
simvastatin, 637
Sirolimus, 959
skin, 172
SLCO1B1, 78
smoking, 611, 737
smoking cessation, 480
sodium-restricted, 822
spacer, 334
spectral analysis, 188
spectrophotometer, 423
spontaneous reporting, 210
SSRI, 761
SSRIs, 767
St John's wort, 701
statin prescribing, 587
subarachnoid haemmorage, 317
sulfadoxine, 493
superoxide dismutase, 22
supersomes, 680
sympathetic activity, 188
synbiotics, 453
synephrine, 833
systematic review, 303

T45G polymorphism, 917
Tacrolimus, 959
target concentration intervention, 502
tesaglitazar, 855
the Faroese population, 134
theophylline, 40, 270, 803
thiopurine, 69
threshold AUC, 629
thrombolysis, 955
time-dependent inhibition, 87
tobramycin, 502
tramadol, 565
transitional milk, 661
treatment outcome, 935
treatment patterns, 775
trial, 942
tricyclic antidepressants, 87
tuberculosis, 418
tuberculosis, 423
Type 2 diabetes, 917

udenafil, 848
UGT1A6, 908
UGT1A9, 893
ulcer, 767
underprescribing, 130
uric acid, 355

vagal nerve, 188
varicella, 203
vildagliptin, 338
VKORC1 haplotypes, 260
voriconazole, 523, 531

warfarin dose, 260
warfarin, 787
wheal and flare reactions, 172
widow spider, 139

zoster, 203

Contents

Volume 65, Number 1, January 2008

Editors' view

1 Editors' view January 2008: *J.M. Ritter*

Review article

3 Overview of the human pharmacokinetics of recombinant activated factor VII: *T. Klitgaard & T.G. Nielsen*

Pharmacokinetics and pharmacodynamics

12 Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions: *S.N. Muchohi, K. Obiero, C.R.J.C. Newton, B.R. Ogutu, G. Edwards & G.O. Kokwaro*

22 The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man: *F.J.F. Broeyer, B.E. van Aken, J. Suzuki, M.J.B. Kemme, H.C. Schoemaker, A.F. Cohen, Y. Mizushima & J. Burggraaf*

30 Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers: *C. Cronenberger, D.R. Mould, H.-J. Roethig & M. Sarkar*

40 Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease: *M.-C. Cyr, M.-F. Beauchesne, C. Lemière & L. Blais*

51 Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism: *E. Schwedhelm, R. Maas, R. Freese, D. Jung, Z. Lukacs, A. Jambrecina, W. Spickler, F. Schulze & R. H. Böger*

Pharmacogenetics

60 Interindividual variability in the concentration–effect relationship of antilymphocyte globulins – a possible influence of FcγRIIIa genetic polymorphism: *D. Ternant, M. Büchler, M. Bénéton, G. Alván, M. Ohresser, G. Touchard, B.H. de Ligny, O. Toupance, H. Watier, Y. Lebranchu & G. Paintaud*

69 IMPDH activity in thiopurine-treated patients with inflammatory bowel disease – relation to TPMT activity and metabolite concentrations: *S. Haglund, J. Taipalensuu, C. Peterson & S. Almer*

78 No significant effect of *SLCO1B1* polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone: *A. Kalliokoski, M. Neuvonen, P.J. Neuvonen & M. Niemi*

Drug interactions

87 Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants: *T.M. Polasek & J.O. Miners*

98 Interaction between midazolam and clarithromycin in the elderly: *S.K. Quinney, B.D. Haehner, M.B. Rhoades, Z. Lin, J.C. Gorski & S.D. Hall*

Drug safety

110 Exposure–response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets: *L. Tothfalusi, S. Speidl & L. Endrenyi*

123 Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study: *G. Corrao, A. Zambon, F. Nicotra, V. Conti, R.E. Nappi & L. Merlino*

Short reports

130 Relationship between polypharmacy and underprescribing: *M.A.J. Kuijpers, R.J. van Marum, A.C.G. Egberts, P.A.F. Jansen*

134 The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population: *J. Halling, P. Weihe & K. Brosen*

139 A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom: *G.K. Isbister, M. O'Leary, M. Miller, S.G.A. Brown, S. Ramasamy, R. James & J.S. Schneider*

Letters to the editors

144 Drug–drug interactions – a preventable patient safety issue?: *J. Strandell, A. Bate, M. Lindquist & I.R. Edwards*

147 Statins and phenytoin interact – a case history: *K.M. Tan, J.G. Kelly & K. McGarry*

149 Neutropenia induced in a patient by treatment with ritodrine: *in vitro* evaluation of myeloid progenitor colony-forming cells: *K. Tsukimori, S. Morokuma, T. Yoshimura, K. Muta & N. Wake*

Volume 65, Number 2, February 2008

Editors' view

151 Sensitivity: real (interferons, odorants) and imagined (homeopathy): *J.M. Ritter*

Review of 2007

154 Clinical pharmacology – providing tools and expertise for translational medicine: *J.K. Aronson, A. Cohen & L.D. Lewis*

Review Article

158 Clinical uses of interferons: *R.M. Friedman*

Commentary

163 The truth about homeopathy: *E. Ernst*

Pharmacodynamics

165 The effect of exercise on the absorption of inhaled human insulin in healthy volunteers: *A.H. Petersen, G. Köhler, S. Korsatko, A. Wutte, M. Wonisch, A. Mautner, B.B. Rønn, P. Clauson, T. Laursen, P. Wollmer & T.R. Pieber*

172 Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine: *N. Frossard, M. Strolin-Benedetti, A. Purohit & G. Pauli*

180 Effect of homeopathy on analgesic intake following knee ligament reconstruction: a phase III monocentre randomized placebo controlled study: *A. Paris, N. Gonnet, C. Chaussard, P. Belon, F. Rocourt, D. Saragaglia & J.L. Cracowski*

188 Effects of direct Cedrol inhalation into the lower airway on autonomic nervous activity in totally laryngectomized subjects:

K. Umeno, E. Hori, M. Tsubota, H. Shojaku, T. Miwa, Y. Nagashima, Y. Yada, T. Suzuki, T. Ono & H. Nishijo

Pharmacokinetics

197 Absolute bioavailability of imidafenacin after oral administration to healthy subjects: *T. Ohno, S. Nakade, K. Nakayama, J. Kitagawa, S. Ueda, H. Miyabe, Y. Masuda & Y. Miyata*

Drug safety

203 Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease: *Y. Mikaeloff, A. Kezouh & S. Suissa*

210 Adverse drug reaction monitoring in a secondary care hospital in South India: *R. Arulmani, S.D. Rajendran & B. Suresh*

Therapeutics

217 Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction: *M.L. Hansen, G.H. Gislason, L. Køber, T.K. Schramm, F. Folke, P. Buch, S.Z. Abildstrom, M. Madsen, S. Rasmussen & C. Torp-Pedersen*

224 The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes: *D.R. Camidge, J.J. Oliver, C. Skinner, B. Attwood, F. Nussey, D. Jodrell & D.J. Webb*

230 The effects of electronic prescribing on the quality of prescribing: *P. Donyai, K. O'Grady, A. Jacklin, N. Barber & B.D. Franklin*

238 Assessment of endothelial function: comparison of the pulse wave response to β_2-adrenoceptor stimulation with flow mediated dilatation: *C. Rambaran, B. Jiang, J.M. Ritter, A. Shah, L. Kalra & P.J. Chowienczyk*

Methods in clinical pharmacology

244 The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD: *Z.L. Borrill, C.M. Houghton, R. Tal-Singer, S.R. Vessey, I. Faiferman, S.J. Langley & D. Singh*

253 Muscular exercise can cause highly pathological liver function tests in healthy men: *J. Pettersson, U. Hindorf, P. Persson, T. Bengtsson, U. Malmqvist, V. Werkström & M. Ekelund*

Short reports

260 Influence of *APOE* genotypes and *VKORC1* haplotypes on warfarin dose requirements in Asian patients: *S. Lal, E. Sandanaraj, S.R. Jada, M.-C. Kong, L.-H. Lee, B.-C. Goh, S.-C. Lee & B. Chowbay*

265 The use of nationwide on-line prescription records improves the drug history in hospitalized patients: *B. Glintborg, H.E. Poulsen & K.P. Dalhoff*

270 Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers: *F.R. Qiu, G.J. Wang, Y.N. Zhao, H. Sun, G.G. Mao, J.Y. A & J. Sun*

Letters to the editors

275 Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful?: *F. Vroom, P.B. van den Berg & L.T.W. de Jong-van den Berg*

277 Noscapine may increase the effect of warfarin: *S. Ohlsson, L. Holm, O. Myrberg, A. Sundström & Q.-Y. Yue*

279 Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms: *A. Tran, F. Bournerias, C.L. Beller, O. Mir, E. Rey, G. Pons, M. Delahousse & J.-M. Tréluyer*

281 Comment on 'The truth about homeopathy' by Ernst: *F. Treuherz*

281 Author's response: *E. Ernst*

Book review

282 Guide to Paediatric Clinical Research: *Edited by K. Rose & J.N. van den Anker*

283 Abstracts of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of 30 March 2007

Volume 65, Number 3, March 2008

Editors' view

299 Pharmacokinetic(s) matters: stroke treatment *et cetera*: *J.M. Ritter*

Editors' report

301 Editors' Report for 2007: *J.M. Ritter*

Review Article

303 Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis: *R. Holland, J. Desborough, L. Goodyer, S. Hall, D. Wright & Y.K. Loke*

Pharmacokinetics and pharmacodynamics

317 Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients followingsubarachnoid haemorrhage: *I. Gueorguieva, S.R. Clark, C.J. McMahon, S. Scarth, N.J. Rothwell, P.J. Tyrell, S.J. Hopkins & M. Rowland*

326 Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate: *X. Jiang, P. Galettis, M. Links, P.L. Mitchell & A.J. McLachlan*

334 Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation: *S.H.R. Mazhar, N.E. Ismail, D.A.G. Newton & H. Chrystyn*

338 The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers: *Y.-L. He, R. Sabo, J. Campestrini, Y. Wang, G.-J. Riviere, J.C. Nielsen, M. Rosenberg, M. Ligueros-Saylan, D. Howard & W.P. Dole*

Pharmacogenetics

347 Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered *Rac*-perhexiline: *B.J. Davies, M.K. Herbert, J.K. Coller, A.A. Somogyi, R.W. Milne & B.C. Sallustio*

Drug interactions

355 Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects: *R. Khosravan, B. Grabowski, J.-T. Wu, N. Joseph-Ridge & L. Vernillet*

Drug safety

364 Knowledge creation about ADRs – turning the perspective from the rear mirror to the projector?: *L. Aagaard, B. Soendergaard, D.I. Stenver & E.H. Hansen*

377 An electronic prompt in dispensing software to promote clinical interventions by community pharmacists: a randomized controlled trial: *J.F. Reeve, P.C. Tenni & G.M. Peterson*

386 Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations: *J. Krska & A.J. Avery*
396 Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study: *U. Mehta, D.N. Durrheim, M. Blockman, T. Kredo, R. Gounden & K.I. Barnes*

Therapeutics

407 Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain: *E. Fernández-Liz, P. Modamio, A. Catalán, C.F. Lastra, T. Rodríguez & E.L. Mariño*

Short reports

418 Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis: *N. Singh, A. Golani, Z. Patel & A. Maitra*
423 Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses: *P. Gupta, V. Roy, G.R. Sethi & T.K. Mishra*
428 Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism: *L. Kóbori, K. Köhalmy, P. Porrogi, E. Sárváry, Z. Gerlei, J. Fazakas, P. Nagy, J. Járay & K. Monostory*
437 Limited frequency of the *CYP2C19*17* allele and its minor role in a Japanese population: *K. Sugimoto, T. Uno, H. Yamazaki & T. Tateishi*

Letters to the editors

440 Erice statement on drug innovation: *G. Velo & P. Rizzini*
442 Current status of clinical pharmacology services provided by Board Certified Clinical Pharmacologists in Japan: *A. Fujimura, H. Yasuhara & S. Nakano*
444 Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects: *W.J. Cubała, J. Landowski & H.M. Wichowicz*

Book reviews

446 Guide for Clinical Trial Staff – Implementing Good Clinical Practice, 3rd Printing: *G. Fortwengel*
447 Drug hypersensitivity: *Edited by W.J. Pichler*
449 Wiley Handbook of Current and Emerging Drug Therapies: *Editorial director: S. Pidgeon*

Volume 65, Number 4, April 2008

Editors' view

451 Minimising Harm: Human Variation and Adverse Drug Reactions (ADRs): *J.M. Ritter*

Review article

453 Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope': *D. Damaskos & G. Kolios*

Commentaries

468 A natural approach to treatment of inflammatory bowel disease: *M. Gruslandi*
470 Prescribing practices for Betahistine: *J.S. Phillips & P.R. Prinsley*

Pharmacodynamics

472 *In vivo* visualization of donepezil binding in the brain of patients with Alzheimer's disease: *N. Okamura, Y. Funaki, M. Tashiro, M. Kato, Y. Ishikawa, M. Maruyama, H. Ishikawa, K. Meguro, R. Iwata & K. Yanai*
480 Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR® inhaled insulin pharmacokinetics and glucodynamics: *A.X. Pan, A. de la Peña, K.P. Yeo, C. Chan, M.T. Loh, S.D. Wise, B.L. Silverman & D.B. Muchmore*

Pharmacokinetics

488 The role of hair follicles in the percutaneous absorption of caffeine: *N. Otberg, A. Patzelt, U. Rasulev, T. Hagemeister, M. Linscheid, R. Sinkgraven, W. Sterry & J. Lademann*
493 Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen: *C. Obua, U. Hellgren, M. Ntale, L.L. Gustafsson, J.W. Ogwal-Okeng, T. Gordi & M. Jerling*
502 Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis – a population pharmacokinetic study: *S. Hennig, R. Norris & C.M.J. Kirkpatrick*
511 Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure: *S. Albers, B. Meibohm, T.S. Mir & S. Läer*
523 Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers: *B. Damle, R. LaBadie, P. Crownover & P. Glue*
531 Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects: *E. Andrews, B.D. Damle, A. Fang, G. Foster, P. Crownover, R. LaBadie & P. Glue*

Pharmacogenetics

540 $P2Y_{12}$ polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease: *A. Bierend, T. Rau, R. Maas, E. Schwedhelm & R.H. Böger*
548 Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients: *D. Hirt, F. Mentré, A. Tran, E. Rey, S. Auleley, D. Salmon, X. Duval, J.-M. Tréluyer & The COPHAR2- ANRS Study Group*
558 Influence of the *CYP2D6*4* polymorphism on dose, switching and discontinuation of antidepressants: *M.J. Bijl, L.E. Visser, A. Hofman, A.G. Vulto, T. van Gelder, B.H.Ch. Stricker & R.H.N. van Schaik*

Drug safety

565 Perforated peptic ulcer and short-term mortality among tramadol users: *M.L. Tørring, A. Riis, S. Christensen, R.W. Thomsen, P. Jepsen, J. Søndergaard & H.T. Sørensen*
573 Incidence of fatal adverse drug reactions: a population based study: *K. Wester, A.K. Jönsson, O. Spigset, H. Druid & S. Hägg*
580 Use of β2 agonists and risk of acute myocardial infarction in patients with hypertension: *F. de Vries, S. Pouwels, M. Bracke, J.-W. Lammers, O. Klungel, H. Leufkens & T. van Staa*

Pharmacoepidemiology

587 'Real-life' reduction in cholesterol with statins, 1993 to 2002: *M.J. Murphy, L. Wei, A.D. Watson & T.M. MacDonald*
593 Determinants of chronic benzodiazepine use in the elderly: A longitudinal study: *H.J. Luijendijk, H. Tiemeier, A. Hofman, J. Heeringa & B.H. Ch. Stricker*

600 Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands: *M.K. Bakker, P. Kölling, P.B. van den Berg, H.E.K. de Walle & L.T.W. de Jong van den Berg*

Short reports

607 Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an $n = 1$ randomized study: *E.G.C. Brain, K. Rezai, F. Lokiec, M. Gutierrez & S. Urien*

611 Pulmonary elimination rate of inhaled ^{99m}Tc-sestamibi radioaerosol is delayed in healthy cigarette smokers: *P. Ruparelia, H.K. Cheow, J.W. Evans, L. Banney, S. Shankar, K.R. Szczepura, A.E. Swift, J.R. Ballinger, N.G. Hartman, E.R. Chilvers & A.M. Peters*

Letters to the editors

615 Safe prescribing by junior doctors: *C.N. Molokwu, N. Sandiford & C. Anosike*

617 Response to 'Communicating Information about Drug Interactions': *D.J. Back & S.E. Gibbons*

619 Similarity of biotechnology-derived medicinal products: specific problems and new regulatory framework: *J.-L. Prugnaud*

621 Prophylactic use of gastro-protective agents in patients on low-dose aspirin: *S. Balakrishnan & R. Jhaj*

Book reviews

623 Textbook of Interventional Cardiovascular Pharmacology: *Edited by N.N. Kipshidze, J. Fareed, J.W. Moses & P.W. Serruys, reviewed by A. Ferro*

624 The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, 9th Edition: Edited *by D. Taylor, C. Paton & R. Kerwin, reviewed by G.E. Jacobs & F. Cohen*

Volume 65, Number 5, May 2008

Editors' view

627 Prescribing in pregnancy and lactation: *E.J. Begg*

Pharmacodynamics

629 An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study: *D. Hirt, B.V. Overmeire, J.-M. Treluyer, J.-P. Langhendries, A. Marguglio, M.J. Eisinger, P. Schepens & S. Urien*

637 Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin: *O. Hussein, L. Minasian, Y. Itzkovich, K. Shestatski, L. Solomon & J. Zidan*

646 Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients: *M.J. Brown & C.B. Toal*

Clinical pharmacology in pregnancy

653 Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004–2006: *A. Engeland, J.G. Bramness, A.K. Daltveit, M. Rønning, S. Skurtveit & K. Furu*

661 Use of a sparse sampling study design to assess transfer of tramadol and its *O*-desmethyl metabolite into transitional breast milk: *K.F. Ilett, M.J. Paech, M. Page-Sharp, S.K. Sy, J.H. Kristensen, R. Goy, S. Chua, T. Christmas & K.L. Scott*

667 Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus: *S. Sudhakaran, C.R. Rayner, J. Li, D.C.M. Kong, N.M. Gude & R.L. Nation*

674 Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers: *I. Law, K.F. Ilett, L.P. Hackett, M. Page-Sharp, F. Baiwog, S. Gomorrai, I. Mueller, H.A. Karunajeewa & T.M.E. Davis*

Drug interactions

680 Application of CYP3A4 *in vitro* data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction: *K.A. Youdim, A. Zayed, M. Dickins, A. Phipps, M. Griffiths, A. Darekar, R. Hyland, O. Fahmi, S. Hurst, D.R. Plowchalk, J. Cook, F. Guo & R.S. Obach*

693 The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers: *T. Tateishi, M. Miura, T. Suzuki & T. Uno*

Drug metabolism

701 The recovery time-course of CYP3A after induction by St John's wort administration: *H. Imai, T. Kotegawa, K. Tsutsumi, T. Morimoto, N. Eshima, S. Nakano & K. Ohashi*

708 Time course of the increase in 4β-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy: *K. Wide, H. Larsson, L. Bertilsson & U. Diczfalusy*

Therapeutics

716 Gap in publication of comparative information on new medicines: *J.C.F. van Luijn, P. Stolk, F.W.J. Gribnau & H.G.M. Leufkens*

723 Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events: *C. Boersma, M.J. Postma, S.T. Visser, J. Atthobari, P.E. de Jong, L.T.W. de Jong-van den Berg & R.T. Gansevoort on behalf of the PREVEND Study Group*

Methods in clinical pharmacology

733 Bromide as marker for drug adherence in hypertensive patients: *R.L. Braam, S.H.M. van Uum, J.W.M. Lenders & T. Thien*

737 Assessment of antitussive efficacy of dextromethorphan in smoking related cough: objective *vs.* subjective measures: *J. Ramsay, C. Wright, R. Thompson, D. Hull & A.H. Morice*

Pharmacogenetics

742 Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure: *M. Zakrzewski-Jakubiak, S. de Denus, M.-P. Dubé, F. Bélanger, M. White & J. Turgeon*

752 Effect of *CYP2C19* *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians: *N.G. Hunfeld, R.A. Mathot, D.J. Touw, R.H. van Schaik, P.G. Mulder, P.F. Franck, E.J. Kuipers & W.P. Geus*

761 Serotonin transporter polymorphism and bleeding time during SSRI therapy: *D.M.C. Hougardy, T.C.G. Egberts, F. van der Graaf, V.J. Brenninkmeijer & L.J.J. Derijks*

767 Increased omeprazole metabolism in carriers of the *CYP2C19*17* allele; a pharmacokinetic study in healthy volunteers: *R.M. Baldwin, S. Ohlsson, R.S. Pedersen, J. Mwinyi, M. Ingelman-Sundberg, E. Eliasson & L. Bertilsson*

Pharmacoepidemiology

775 Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom: *T.M. MacDonald & S.V. Morant*

Short report

787 A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation: *U.P. Kulkarni, B.D. Swar, D.R. Karnad, S. Davis, A.M. Patwardhan, N.A. Kshirsagar & N.J. Gogtay*

Letters to the editors

791 Study of *ABCB1* polymorphism (C3435T) in HIV-1-infected individuals from South India: *S. Bakshi, G. Ramachandran, K. Ramesh, A.K. Hemanthkumar, S. Anitha, C. Padmapriyadarsini, G. Narendran, P.A. Menon, S. Rajasekaran & S. Swaminathan*

793 Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen: *F. Bürki, K. Badie, P. Bartoli, P. Bernard, J.L. Montastruc & H. Bagheri*

795 Fixed dose drug combinations (FDCs): rational or irrational: a view point: *C.S. Gautam & L. Saha*

797 Melatonin treatment does not improve rheumatoid arthritis: *G.J. Maestroni, K. Otsa & M. Cutolo*

Book review

799 The Oxford Handbook of Clinical Pharmacy: *Edited by P. Wiffen, M. Mitchell, M. Snelling & N. Stoner; reviewed by H.-J. Guchelaar*

Volume 65, Number 6, June 2008

Editor's View

801 Drug regulation & therapeutic efficacy: *J.M. Ritter*

Review article

803 Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment: *G.P. Currie, C.A. Butler, W.J. Anderson & C. Skinner*

Pharmacodynamics

811 Brain histamine H_1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with ^{11}C-doxepin: *M. Tashiro, X. Duan, M. Kato, M. Miyake, S. Watanuki, Y. Ishikawa, Y. Funaki, R. Iwata, M. Itoh & K. Yanai*

822 Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans: *H. Vase, T.G. Lauridsen, J.N. Bech & E.B. Pedersen*

833 Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions: *C.A. Haller, M. Duan, P. Jacob III & N. Benowitz*

841 Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose–response study: *C.I. Whale, M.P. Sovani, K.J. Mortimer, T.W. Harrison & A.E. Tattersfield*

848 Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects: *B.-H. Kim, H.-S. Lim, J.-Y. Chung, J.-R. Kim, K.S. Lim, D.-R. Sohn, J.-Y. Cho, K.-S. Yu, S.-G. Shin, J.-S. Paick & I.-J. Jang*

Pharmacokinetics

855 Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion: *B. Hamrén, H. Ericsson, O. Samuelsson & M.O. Karlsson*

864 Acute passive cigarette smoke exposure and inhaled human insulin (Exubera®) pharmacokinetics: *R. Fountaine, A. Milton, T. Checchio, G. Wei, M. Stolar, J. Teeter, R. Jaeger & D. Fryburg*

871 Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens: *D.A. Hughes*

879 Diclofenac readily penetrates the cerebrospinal fluid in children: *H. Kokki, E. Kumpulainen, M. Laisalmi, J. Savolainen, J. Rautio & M. Lehtonen*

885 Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia: *Y. Wang, L. Zhou, C. Dutreix, E. Leroy, Q. Yin, V. Sethuraman, G.-J. Riviere, O.Q.P. Yin, H. Schran & Z.-X. Shen*

Pharmacogenetics

893 Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9: *Z. Jiao, J.-J. Ding, J. Shen, H.-Q. Liang, L.-J. Zhong, Y. Wang, M.-K. Zhong & W.-Y. Lu*

908 UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers: *L.M.G. Limenta, T. Jirasomprasert, J. Tankanitlert, S. Svasti, P. Wilairat, U. Chantharaksri, S. Fucharoen & N.P. Morales*

917 The association of adiponectin allele *45T/G* and *–11377C/G* polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients: *H. Sun, Z.-C. Gong, J.-Y. Yin, H.-L. Liu, Y.-Z. Liu, Z.-W. Guo, H.-H. Zhou, J. Wu & Z.-Q. Liu*

Drug safety and information

927 Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases: *P. McGettigan, P. Han, L. Jones, D. Whitaker & D. Henry*

935 Clinically informative measures of the effect of drugs or other interventions: *L.R. Salmi, S. Suissa, G. Chêne & R. Salamon*

Methodology

942 Trends in the methodological quality of published randomized controlled trials on antibacterial agents: *M.E. Falagas, E.I. Pitsouni & I.A. Bliziotis*

Short Reports

955 Thrombolysis or nothing for acute myocardial infarction? It's all the same!: *V. Bertele', L. Angelici, S. Barlera & S. Garattini*

959 Graft rejection: pharmacogenetic analysis or drug anamnesis?: *V.V. Pham, D.O. Stichtenoth & J. Borlak*

Letters to the editors

961 Assessing general practitioners' prescribing behaviour in elderly patients with concealed renal failure: *A.P. Jonville-Béra, L. Paroux & E. Autret-Leca*

964 Lean body mass normalizes the effect of obesity on renal function: *S. Janmahasatian, S.B. Duffull, A. Chagnac, C.M.J. Kirkpatrick & B. Green*

966 A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient: *H. Blasco, M. Boisdron-Celle, P. Bougnoux, G. Calais, J.-F. Tournamille, J. Ciccolini, E. Autret-Leca & C.L. Guellec*

971 Suspected drug reaction with piperacillin/tazobactam, in a premature infant: *H. Maulidi, S. Godambe & P. Chow*

973 Corrigendum

974 Proceedings of the British Pharmacological Society Clinical Pharmacology Section 17–20 December 2007 Hilton Metropole Hotel, Brighton

1007 Indexes for Volume 65